Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Status:
Completed
Trial end date:
2020-04-07
Target enrollment:
Participant gender:
Summary
This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in
patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and
did not have a palpable spleen.